Skip to main content
OpenTrials

Clinical trial condition

Neisseriaceae Infections

Explore clinical trials studying Neisseriaceae Infections. Study availability and eligibility vary by location and protocol.

400 public trials 21 recruiting studies
Refine in advanced search Browse all conditions

Neisseriaceae Infections trial results

Completed

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

NCT00808028

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +11 more
Locations
  • Queensland Paediatric Infectious Diseases (QPID) Laboratory Herston, Queensland, Australia
  • Department of Paediatrics, Women's & Children's Hospital North Adelaide, South Australia, Australia
  • Royal Children's Hospital Carlton, Victoria, Australia
  • Children's Clinical Research Facility, Vaccine Trials Group (VTG), Subiaco, Western Australia, Australia
View all 27 locations
View Trial Details
Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

NCT01139021

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • amostatná ordinace praktického lékaře pro děti a dorost Jindřichův Hradec Hradec, Czechia
  • Dětské oddělení nemocnice Náchod Náchod, Czechia
  • Dětské oddělení nemocnice Pardubice Pardubice, Czechia
  • University of Tampere Medical School, Vaccine Research Center Tampere Biokatu 10, Pirkanmaa, Finland
View all 19 locations
View Trial Details
Completed

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

NCT00937521

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +12 more
Locations
  • Hospital Privado de Córdoba CMC SA Naciones Unidas 346, Córdoba Province, Argentina
  • Universidad de Chile, Av Independencia 1027 Comuna de Independencia, Santiago Metropolitan, Chile
  • Consultorio Manuel Bustos Lo Cruzat 486, Quilicura, Santiago Metropolitan, Chile
  • Samostatna ordinace praktickeho lekare pro deti a dorost O. Kubina 17, Boskovice, Czechia
View all 38 locations
View Trial Details
Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

NCT00721396

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +3 more
Locations
  • Novartis Investigational Site Nr. 59 Edegem, Antwerpen, Belgium
  • Novartis Investigational Site Nr. 55 Antwerp, Belgium
  • Study Investigational Site Nr. 60 Brussels, Brussels Capital, Belgium
  • Novartis Investigational Site Nr. 57 Brussels, Brussels Capital, Belgium
View all 60 locations
View Trial Details
Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NCT01352793

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +11 more
Locations
  • Accelovance,Inc. Huntsville, Alabama, United States
  • Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC Chandler, Arizona, United States
  • Clinical Research Advantage, Inc/ East Valley Family Physicians, PLC Chandler, Arizona, United States
  • Cassidy Medical Group/Clinical Research Advantage Tempe, Arizona, United States
View all 86 locations
View Trial Details
Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

NCT00847145

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Altenburger Eisenstadt, Austria
  • Grässl Hall in Tirol, Austria
  • Häckel Kirchdorf, Austria
  • Prieler Neufeld A.d. Leitha, Austria
View all 59 locations
View Trial Details
Completed

Safety of MenACWY-CRM Vaccination in Adolescents

NCT01452464

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +12 more
Locations
  • Riverside Medical Center Campus, 10800 Magnolia Ave Riverside, California, United States
  • San Diego Medical Center Campus, 4647 Zion Ave 92120 San Diego, California, United States
  • Fontana Medical Center Campus Valley Annex, 16994 E. Valley Blvd., Fontana, California, United States
View Trial Details
Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

NCT01423084

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +13 more
Locations
  • Royal Children's Hospital Herston, Queensland, Australia
  • AusTrials Pty Ltd-Suites 6, 10 & 11, Peninsula Specialist Centre Kippa-Ring, Queensland, Australia
  • AusTrials Pty Ltd-Suite 5, Level 1, 14 Primrose Street Sherwood, Queensland, Australia
  • Women's and Children's Hospital, 72 King William Road North Adelaide, South Australia, Australia
View all 13 locations
View Trial Details

Related conditions